Bank of Montreal’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-100,000
Closed -$3.46M 4537
2021
Q1
$3.46M Buy
+100,000
New +$3.56M ﹤0.01% 1524
2020
Q1
Sell
-3,200
Closed -$93K 4509
2019
Q4
$93K Buy
+3,200
New +$88.6K ﹤0.01% 3535

Other funds holding NVO

Bank of Montreal's NVO Position: Q1 2026 in Review

Bank of Montreal reduced its Novo Nordisk (NVO) stake by 77% in Q1 2026, selling an estimated $91.8M and leaving 589,107 shares worth $21.6M. The position accounts for 0.01% of the portfolio, ranked #820.

Bank of Montreal first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $266M in Q3 2023. 1,276 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Bank of Montreal held 589,107 shares of Novo Nordisk worth $21.6M as of Q1 2026.
  • Bank of Montreal sold 1,936,720 Novo Nordisk shares in Q1 2026, an estimated $91.8M.
  • Novo Nordisk made up 0.01% of Bank of Montreal's portfolio in Q1 2026, its #820 holding.
  • Bank of Montreal first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • Bank of Montreal's Novo Nordisk position peaked at $266M in Q3 2023.
  • 1,276 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.